High Efficacy and Improvement in CPT Class With Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients With CPT C Decompensated Cirrhosis

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria


High Efficacy and Improvement in CPT Class With Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients With CPT C Decompensated Cirrhosis

	Reported by Jules Levin EASL April 10-14, 2019, Vienna, Austria